Schedule 13D ownership disclosure

LAKEFRONT BIOTHERAPEUTICS NV

Ordinary Shares, no par value · CUSIP: 36315X101

Event date: 2025-02-07

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • TANG CAPITAL MANAGEMENT, LLCReported CIK 0001232621

    Shares: 4,910,525.00 · Class: 7.5%

  • KEVIN TANGReported CIK 0001178579

    Shares: 4,910,525.00 · Class: 7.5%

  • TANG CAPITAL PARTNERS, LPReported CIK 0001191935

    Shares: 2,723,147.00 · Class: 4.2%

  • TANG CAPITAL PARTNERS INTERNATIONAL, LP

    Shares: 1,962,418.00 · Class: 3.0%

  • TANG CAPITAL PARTNERS III, INC

    Shares: 224,960.00 · Class: 0.3%

  • TANG CAPITAL PARTNERS IV, INC

    Shares: 0.00 · Class: 0%

  • CONCENTRA BIOSCIENCES, LLCReported CIK 0001970065

    Shares: 0.00 · Class: 0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001214659-25-002917
Form type
SCHEDULE 13D
Filer
Lakefront Biotherapeutics NV
CIK
CIK 1421876
Filed
Feb 14, 2025
Reporting period
Feb 07, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub